Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

This grant supports preclinical and patient-based research on how incretin mimetics (GLP-1, GIP-1, or dual agents) affect cancer risk. It funds studies that investigate the underlying mechanisms of risk changes rather than short-term outcomes such as weight loss or diabetes.

Amount: Not stated
Type: Grant

Key facts

Key facts for Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Amount	Not stated
Issuer	National Institutes of Health
Who can apply	Small businesses, companies, universities and 7 more
Sectors	EdTech · HealthTech
Deadline	Closes 07 Jan 2027

Unlock application details

See all eligibility criteria, required documents and the official application link. Free account, no card.

Update history

Source: grants.gov ↗

Source checked 2 days ago

85 days agoagentImported from the official source

Opportunities with the same funding type or region
European Degree Exploratory Action		Closes 18 Feb 2027
Cooperative Agreement for affiliated Partner with Alaska Cooperative Ecosystem Studies Unit	up to $234,460	Closes 07 Dec 2026
Cooperative Agreement for affiliated Partner with Colorado Plateau Cooperative Ecosystem Studies Unit	up to $150,000	Closes 07 Dec 2026